Chromatin proteins and modifications as drug targets

Nature

Volumn 502, Issue 7472, 2013, Pages 480-488

  Helin, Kristian ^a,b   Dhanak, Dashyant ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMATIN ASSOCIATED PROTEIN; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE INHIBITOR; EPZ 004777; EPZ 005687; EPZ 5676; GSK 126; GSK 323; GSK 343; HISTONE DEACETYLASE INHIBITOR; HISTONE DEMETHYLASE; HISTONE DEMETHYLASE INHIBITOR; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE INHIBITOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; PROTEIN; PROTEIN ARGININE METHYLTRANSFERASE; PROTEIN DOT1L; PROTEIN LYSINE METHYLTRANSFERASE; PROTEIN TET2; SGC 0946; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER; CHROMOSOME; DISEASE; DISEASE TREATMENT; DNA; DRUG; GENE EXPRESSION; INHIBITOR; PROTEIN;

CANCER THERAPY; CHROMOSOME TRANSLOCATION; CONTINUOUS INFUSION; DNA METHYLATION; DNA MODIFICATION; DRUG TARGETING; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CHROMATIN; HISTONE DEMETHYLASES; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN STRUCTURE, TERTIARY;

EID: 84886808679     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature12751     Document Type: Review

References (103)

1. Berger, S. L. The complex language of chromatin regulation during transcription. Nature 447, 407-412 (2007).
2. Kouzarides, T. Chromatin modifications and their function. Cell 128, 693-705 (2007).
3. Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome-biological and translational implications. Nature Rev. Cancer 11, 726-734 (2011).
4. Issa, J. P. & Kantarjian, H. M. Targeting DNA methylation. Clin. Cancer Res. 15, 3938-3946 (2009).
5. Yang, X., Lay, F., Han, H. & Jones, P. A. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol. Sci. 31, 536-546 (2010).
6. Khan, O. & La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell Biol. 90, 85-94 (2012).
7. Wagner, J. M., Hackanson, B., Lubbert, M. & Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenetics 1, 117-136 (2010).
8. You, J. S. & Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9-20 (2012).
9. Huang, J. et al. p53 is regulated by the lysine demethylase LSD1. Nature 449, 105-108 (2007).
10. Wu, S. C. & Zhang, Y. Role of protein methylation and demethylation in nuclear hormone signaling. Mol. Endocrinol. 23, 1323-1334 (2009).
11. Zhang, K. & Dent, S. Y. Histone modifying enzymes and cancer: going beyond histones. J. Cell. Biochem. 96, 1137-1148 (2005).
12. Robinson, G. et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488, 43-48 (2012).
13. Ryan, R. J. & Bernstein, B. E. Genetic events that shape the cancer epigenome. Science 336, 1513-1514 (2012).
14. Shih, A. H., Abdel-Wahab, O., Patel, J. P. & Levine, R. L. The role of mutations in epigenetic regulators in myeloid malignancies. Nature Rev. Cancer 12, 599-612 (2012).
15. McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc. Natl Acad. Sci. USA 109, 2989-2994 (2012).
16. Sneeringer, C. J. et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc. Natl Acad. Sci. USA 107, 20980-20985 (2010).
17. Kuo, A. J. et al. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol. Cell 44, 609-620 (2011).
18. Meyer, C. et al. New insights to the MLL recombinome of acute leukemias. Leukemia 23, 1490-1499 (2009).
19. Okada, Y. et al. hDOT1L links histone methylation to leukemogenesis. Cell 121, 167-178 (2005).
20. Bernt, K. M. et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 20, 66-78 (2011).
21. Daigle, S. R. et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53-65 (2011).
22. Anglin, J. L. et al. Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L. J. Med. Chem. 55, 8066-8074 (2012).
23. Yu, W. et al. Bromo-deaza-SAH: a potent and selective DOT1L inhibitor. Bioorg. Med. Chem. 21, 1787-1794 (2013).
24. Daigle, S. R. et al. Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood http://dx.doi.org/10.1182/blood-2013-04-497644 (2013).
25. Morey, L. & Helin, K. Polycomb group protein-mediated repression of transcription. Trends Biochem. Sci. 35, 323-332 (2010).
26. Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629 (2002).
27. Dalgliesh, G. L. et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 463, 360-363 (2010).
28. van Haaften, G. et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nature Genet. 41, 521-523 (2009).
29. Kleer, C. G. et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl Acad. Sci. USA 100, 11606-11611 (2003).
30. Wagener, N. et al. Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer 10, 524 (2010).
31. Takawa, M. et al. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci. 102, 1298-1305 (2011).
32. Bracken, A. P. et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323-5335 (2003).
33. Morin, R. D. et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genet. 42, 181-185 (2010).
34. Pasqualucci, L. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genet. 43, 830-837 (2011).
35. Ryan, R. J. et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS ONE 6, e28585 (2011).
36. Nikoloski, G. et al. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nature Genet. 42, 665-667 (2010).
37. McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108-112 (2012).
38. Knutson, S. K. et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chem. Biol. 8, 890-896 (2012).
39. Qi, W. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl Acad. Sci. USA 109, 21360-21365 (2012).
40. Valente, S. et al. Identification of PR-SET7 and EZH2 selective inhibitors inducing cell death in human leukemia U937 cells. Biochimie 94, 2308-2313 (2012).
41. Epizyme Inc. Inhibitors of human EZH2, and methods to use thereof. WO/2012/034132 (2012).
42. Tan, J. et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 21, 1050-1063 (2007).
43. Miranda, T. B. et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8, 1579-1588 (2009).
44. Knutson, S. K. et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl Acad. Sci. USA 110, 7922-7927 (2013).
45. Kooistra, S. M. & Helin, K. Molecular mechanisms and potential functions of histone demethylases. Nature Rev. Mol. Cell Biol. 13, 297-311 (2012).
46. Mosammaparast, N. & Shi, Y. Reversal of histone methylation: biochemical and molecular mechanisms of histone demethylases. Annu. Rev. Biochem. 79, 155-179 (2010).
47. Yang, Z. Q. et al. Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines. Cancer Res. 60, 4735-4739 (2000).
48. Liu, G. et al. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene 28, 4491-4500 (2009).
49. Ehrbrecht, A. et al. Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological components. J. Pathol. 208, 554-563 (2006).
50. Lu, P. J. et al. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J. Biol. Chem. 274, 15633-15645 (1999).
51. Hayami, S. et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol. Cancer 9, 59 (2010).
52. He, J., Nguyen, A. T. & Zhang, Y. KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia. Blood 117, 3869-3880 (2011).
53. Jensen, L. R. et al. Mutations in the JARID1C gene, which is involved in transcriptional regulation and chromatin remodeling, cause X-linked mental retardation. Am. J. Hum. Genet. 76, 227-236 (2005).
54. Laumonnier, F. et al. Mutations in PHF8 are associated with X linked mental retardation and cleft lip/cleft palate. J. Med. Genet. 42, 780-786 (2005).
55. Kruidenier, L. et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 488, 404-408 (2012).
56. Lynch, J. T., Harris, W. J. & Somervaille, T. C. LSD1 inhibition: a therapeutic strategy in cancer? Expert Opin. Ther. Targets 16, 1239-1249 (2012).
57. Hayami, S. et al. Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int. J. Cancer 128, 574-586 (2011).
58. Kauffman, E. C. et al. Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol. Carcinog. 50, 931-944 (2011).
59. Kahl, P. et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66, 11341-11347 (2006).
60. Schulte, J. H. et al. Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res. 69, 2065-2071 (2009).
61. Harris, W. J. et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 21, 473-487 (2012).
62. Schenk, T. et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nature Med. 18, 605-611 (2012).
63. Oryzon Genomics. Phenylcyclopropylamine derivatives and their medical use. WO/2010/084160 (2010).
64. Ram, O. et al. Combinatorial patterning of chromatin regulators uncovered by genome-wide location analysis in human cells. Cell 147, 1628-1639 (2011).
65. Whyte, W. A. et al. Enhancer decommissioning by LSD1 during embryonic stem cell differentiation. Nature 482, 221-225 (2012).
66. Maes, T. et al. Preclinical characterization of a potent and selective inhibitor of the histone demethylase KDM1A for MLL leukemia. J. Clin. Oncol. 31, suppl; abstr. e13543 (2013).
67. Lee, M. G., Wynder, C., Schmidt, D. M., McCafferty, D. G. & Shiekhattar, R. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem. Biol. 13, 563-567 (2006).
68. Zuccato, C. et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nature Genet. 35, 76-83 (2003).
69. Liang, Y., Vogel, J. L., Narayanan, A., Peng, H. & Kristie, T. M. Inhibition of the histone demethylase LSD1 blocks α-herpesvirus lytic replication and reactivation from latency. Nature Med. 15, 1312-1317 (2009).
70. Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231 (2012).
71. Gyuris, A. et al. The chromatin-targeting protein Brd2 is required for neural tube closure and embryogenesis. Biochim. Biophys. Acta 1789, 413-421 (2009).
72. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
73. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
74. Mitsubishi-Tanabe Pharma Corporation. Antitumor agent. WO/2009/084693 (2009).
75. French, C. A. Demystified molecular pathology of NUT midline carcinomas. J. Clin. Pathol. 63, 492-496 (2010).
76. Dawson, M. A. et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533 (2011).
77. Delmore, J. E. et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904-917 (2011).
78. Puissant, A. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308-323 (2013).
79. Béguelin, W. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23, 677-692 (2013).
80. Ernst, T. et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nature Genet. 42, 722-726 (2010).
81. Ntziachristos, P. et al. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nature Med. 18, 298-301 (2012).
82. Simon, C. et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26, 651-656 (2012).
83. Zhang, J. et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481, 157-163 (2012).
84. Lewis, P. W. et al. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science 340, 857-861 (2013).
85. Stronach, E. A. et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res. 71, 4412-4422 (2011).
86. Yu, W. et al. Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors. Nature Commun. 3, 1288 (2012).
87. Amatangelo, M. D. et al. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12, 2113-2119 (2013).
88. Structural Genomics Consortium. Chemical Probes. http://www.thesgc.org/ scientists/chemical-probes (SGC, 2013).
89. Konze, K. D. et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem. Biol. 8, 1324-1334 (2013).
90. Kubicek, S. et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell 25, 473-481 (2007).
91. Liu, F. et al. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2, 4-diamino-7-aminoalkoxy- quinazolines. J. Med. Chem. 53, 5844-5857 (2010).
92. Vedadi, M. et al. A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chem. Biol. 7, 566-574 (2011).
93. Yuan, Y. et al. A small-molecule probe of the histone methyltransferase G9a induces cellular senescence in pancreatic adenocarcinoma. ACS Chem. Biol. 7, 1152-1157 (2012).
94. Liu, F. et al. Exploiting an allosteric binding site of PRMT3 yields potent and selective inhibitors. J. Med. Chem. 56, 2110-2124 (2013).
95. Wan, H. et al. Benzo[d]imidazole inhibitors of coactivator associated arginine methyltransferase 1 (CARM1)-hit to lead studies. Bioorg. Med. Chem. Lett. 19, 5063-5066 (2009).
96. Sack, J. S. et al. Structural basis for CARM1 inhibition by indole and pyrazole inhibitors. Biochem. J. 436, 331-339 (2011).
97. Allan, M. et al. N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5- carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1). Bioorg. Med. Chem. Lett. 19, 1218-1223 (2009).
98. Seal, J. et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 22, 2968-2972 (2012).
99. Picaud, S. et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 73, 3336-3346 (2013).
100. Herold, J. M. et al. Small-molecule ligands of methyl-lysine binding proteins. J. Med. Chem. 54, 2504-2511 (2011).
101. James, L. I. et al. Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nature Chem. Biol. 9, 184-191 (2013).
102. Metzger, E. et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 437, 436-439 (2005).
103. Wissmann, M. et al. Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression. Nature Cell Biol. 9, 347-353 (2007).